Steadybase.

HUTCHMED (China) Ltd.

Investor relations LinkedIn
  • HCM · Nasdaq
  • Pharmaceutical Preparations
  • Hong Kong, Hong Kong
  • CIK 0001648257

Updated from SEC filings through

Top things to know

Executives

HUTCHMED (China) Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Hong Kong, Hong Kong. It trades as HCM on Nasdaq. Revenue was $549M in the fiscal year ending December 31, 2025, -13.0% from the year before.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue $549M
20-F, 2026-03-05
$630M
20-F, 2026-03-05
$838M
20-F, 2026-03-05
$426M
20-F, 2023-02-28
$356M
20-F, 2023-02-28
Operating income -$39.2M
20-F, 2026-03-05
-$43.7M
20-F, 2026-03-05
$18.4M
20-F, 2026-03-05
-$408M
20-F, 2025-03-19
-$328M
20-F, 2024-02-28
SG&A $66.7M
20-F, 2026-03-05
$64.3M
20-F, 2026-03-05
$79.8M
20-F, 2026-03-05
$92.2M
20-F, 2025-03-19
$89.3M
20-F, 2024-02-28
Net income $457M
20-F, 2026-03-05
$37.7M
20-F, 2026-03-05
$101M
20-F, 2026-03-05
-$361M
20-F, 2025-03-19
-$195M
20-F, 2024-02-28

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Chig Fung Cheng Acting CEO and CFO Form 4, May 21, 2026
Wei-guo Su CEO and CSO Form 4, May 21, 2026
Lorenso Chiu
Senior Vice President Finance - Business Development & Reporting
Deputy Chief Financial Officer Form 4, May 21, 2026
Charles George Rupert Nixon Group General Counsel Form 4, May 21, 2026

What HUTCHMED (China) Ltd does

We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 872.3 million (as of December 31, 2025) 20-F, March 5, 2026
Auditor PricewaterhouseCoopers Zhong Tian LLP (Shenzhen, the People’s Republic of China) Latest 10-K

Recent 8-K events

No 8-K filings on file.

Frequently asked questions about HUTCHMED (China) Ltd

What does HUTCHMED (China) Ltd do?
In its own words, from Item 1 of its 10-K: "We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally."
What is HUTCHMED (China) Ltd's revenue?
$549M for the fiscal year ending December 31, 2025, from its 20-F filed March 5, 2026.
Is HUTCHMED (China) Ltd profitable?
HUTCHMED (China) Ltd reported net income of $457M for the fiscal year ending December 31, 2025.
Who is the CFO of HUTCHMED (China) Ltd?
Chig Fung Cheng, Acting CEO and CFO, as named in a 4 filed May 21, 2026.
Where is HUTCHMED (China) Ltd headquartered?
Hong Kong, Hong Kong.
What is HUTCHMED (China) Ltd's stock ticker?
HCM, HMDCF on Nasdaq.
What industry is HUTCHMED (China) Ltd in?
Pharmaceutical Preparations, SIC code 2834.
Is HUTCHMED (China) Ltd a public company?
Yes. HUTCHMED (China) Ltd files with the SEC under CIK 0001648257 and trades as HCM.
Who audits HUTCHMED (China) Ltd?
PricewaterhouseCoopers Zhong Tian LLP, Shenzhen, the People’s Republic of China, as named in its latest annual report (10-K).
How many shares of HUTCHMED (China) Ltd are outstanding?
872.3 million shares as of December 31, 2025, from its 20-F filed March 5, 2026.